# G4

# Quality System Regulation Coverage

# **QSIT VALIDATION WORKSHEET**

Item #	Goal/Outcome	
G4	Provide broad and adequate	coverage of the Quality System Regulation when
(Activity 1)	_	e Quality System inspection.
Term <sup>1</sup>	Type of activity (test or analysis)	Parameter(s) to be measured
Short	Analysis	QSIT Inspectional Objectives and narrative "linkages" described within the "QSIT Inspection Handbook"
Scope and	C OCIT I Objectives	and "linkages" with the requirements of the OS Deculation
nature of the process to be		s and "linkages" with the requirements of the QS Regulation. for the inspection of the requirements of the QS Regulation either is or indirectly through "linkages".
followed. <sup>2</sup>	"SUBSYSTEM PURPOSE, TOOLS A REGULATION" as the tool for compa the QS Regulation to determine if any 'QSIT Inspectional Objectives and "link any "gaps" exist between the inspection Regulation (via CSO Nelson's model).	using CSO Chris Nelson's (FDA, CDRH GMP Expert) model ND RELATED SECTIONS OF THE QUALITY SYSTEM rison. CSO Nelson's model will be compared to the requirements of 'gaps" exist between CSO Nelson's model and the regulation. The tages" will be compared against CSO Nelson's model to determine if and requirements of QSIT and the regulatory requirements of the QS CSO Nelson's model was selected as an intermediary document frements of the QS Regulation with the concept of a quality system R. Ruff (HFR-CE350)
Acceptance	QSIT Inspectional Objectives and "linkages" provide for the inspection of the requirements of the QS	
criteria (if	Regulation.	
known)		
	th the activity measures/confirms	This activity will provide direct and objective evidence
how well the goal/outcome has been met. <sup>3</sup>		that while fulfilling the requirements necessary to meet
(strengths and weaknesses of this validation		QSIT Inspectional Objectives, the requirements of the
activity)		QS Regulation are inspected. Since we are comparing
		the requirements of QSIT to the QS Regulation
		requirements, there are no apparent weaknesses in this
	, said as s	activity.
	y the activity represents one of the	
	hes to measuring the	QSIT provides for the inspection of the requirements o
accomplishme	ent of the goal/outcome.	the QS Regulation.

Rev.12/18/98

<sup>&</sup>lt;sup>1</sup> Short term = pre-deployment event, long-term = post-deployment event

<sup>&</sup>lt;sup>2</sup> Describe who, what, where, when, and how. Include an identification of baseline data that may be useful for comparing QSIT performance to the existing approach.

<sup>&</sup>lt;sup>3</sup> Include a discussion of any limitations in the ability of the activity to objectively measure the goal/outcome.

# QSIT VALIDATION ACTIVITY REPORT

Item #	Goal/Outcome	
G4	Provide broad and adequate coverage of the Quality System Regulation when conducting a	
	comprehensive Quality System i	
Activity #	Type of activity (test or analysis)	Parameter(s) to be measured
1	Analysis	QSIT Inspectional Objectives and narrative "linkages" described within the "QSIT Inspection Handbook"
Acceptance	QSIT Inspectional Objectives and "lin	kages" provide for the inspection of the requirements of the QS
Criteria	Regulation.	
Summary of Results	Nelson's model "SUBSYSTEM PURI SYSTEM REGULATION" appears w comparison of the OSIT Handbook In:	the Quality System Regulation (21 CFR Part 820) with CSO Chris POSE, TOOLS AND RELATED SECTIONS OF THE QUALITY in a straightful straightfu
	Concerning CSO Nelson's model, two ("820.1 Scope" and "820.3 Definitions	sections of the QS Regulation were not captured within the model s").
	via Inspectional Objectives or narrativ Scope", "820.3 Definitions", "820.60 requirements of 820.70 captured), "82	ve sections of the QS Regulation were not directly captured for review e discussions or indirectly through linkages. The sections were: "820.1 Identification", "820.65 Traceability", "820.70(f) Buildings" (all other 0.86 Acceptance Status", "820.120 Device Labeling" (requirements Handling", "820.150 Storage", "820.160 Distribution", "820.170 er than 820.180(c)).
	On 3/3/99, a meeting was held between CSO Robert Ruff, NWJ-DO (sub-team leader of "QSIT Handbook Content" sub-team) and CSO Corinne Tylka, CDRH OC (acting sub-team leader in CSO Ruff's absence) to discuss and agree upon the changes required to address the deficiencies of the QSIT Handbook. The "Comments" column of Attachment 1 contains descriptions of the corrective actions (changes to the QSIT Handbook) necessary to address the deficiencies. CSO Tylka was assigned the responsibility for coordinating the change activities with CDRH OC support staff. CSO Tylka and/or CSO Ruff will verify that the appropriate changes have been implemented and a final QSIT Handbook will be available NLT 4/1/99.  Activity references: (1) 21 CFR Part 820 (2) CSO Nelson's "SUBSYSTEM PURPOSE, TOOLS AND	
	Activity references: (1) 21 CFR Part 820 (2) CSO Nelson's "SUBSYSTEM PURPOSE, TOOLS AND RELATED SECTIONS OF THE QUALITY SYSTEM REGULATION" (3) "QSIT INSPECTION HANDBOOK October 1998 Draft"	
Conclusion	The findings do [X] do not [] meet the acceptance criteria for this activity.	
Additional Comments	21 CFR Part 820, Sections "820.1 Sc general training. Therefore, these see QSIT Handbook.	ope" and "820.3 Definitions" are captured within an Investigator's ctions are not specifically captured within the text or linkages of the
Activity Cha	mpion(s) Robert G. Ruff. (	CSO (HFR-CE350)

SSIT Validation Item G4: Provide broad and adequate coverage of the Quality system Regulation when conducting a comprehensive Quality system inspection.

(ey: MC = Management Controls DC = Design Controls CAPA = Corrective and Preventive Actions P&PC = Production and Process Controls SPC = Sterilization Process Controls |
)1, 02... = Objective 1, Objective 2, etc. L = Linkage FC = Flow Chart Examples: 820.20(a) Quality Policy is covered by QSIT "MCO1" and "MCO2" = Management Control |
)bjectives I and 2; If the requirement is covered by QSIT "P&PCO2L", it is covered by a "Linkage" from P&PC Objective 2. G4 Activity I Attach. I 3 pp.

Ouality System Regulation	CSO Neison's Augument	USII Coverage	
820.1(a)-(e) Scope	No	No	Training issue
820.3 (a) –(aa) Definitions	No	No	Training issue
820.5 Quality System	Yes	Yes ("Getting Started")	Confirmation is an ultimate goal of QS11
820.20 Management Respon.	Section Title	Section Title	
820.20(a) Quality Policy	Yes	Yes (MCO1, MCO2)	
820.20(b) Organization	Yes	Yes (MCO3, MCO4)	
820.20(b)(1) Resp. and Auth.	Yes	Yes (MCO3)	
820.20(b)(2) Resources	Yes	Yes (MCO3)	
820.20(b)(3) Management Rep.		Yes ("Getting Started", MCO4)	
820.20(c) Management Review	Yes (Mgt and Fac. & Equip.)	Yes (MCO1, MCO5, CAPAO10)	
820.20(d) Quality planning	Yes	Yes (MCO1)	
820.20(e) Quality system proc.s	Yes	Yes (MCO1)	
820.22 Quality Audit	Yes	Yes (MCO6)	
820.25 Personnel	Section Title	Section Title	
820.25(a) General	Yes	Yes (P&PCO6L, SPCO5L)	
820.25(b) Training	Yes (Mgt and P&PC)	Yes (P&PCO6, SPCO5)	
820.30 Design Control	Section Title	Section Title	
820.30(a) General	Yes	Yes (DCO1)	
820,30(b) Design and Dev. Plan.	Yes	Yes (DCO3)	
820.30(c) Input	Yes	Yes (DCO2, DCO4)	
820 30(d) Output	Yes	Yes (DCO2, DCO5)	
820 30(e) Review	Yes	Yes (DC02, DC014)	
820 30(f) Verification	Yes	Yes (DCO2, DCO6, DCO7)	
(820,30(t) Validation	Yes	Yes (DCO2, DCO6, DCO8 - DCO12)	
820 30(b) Transfrer	Yes	Yes (DCO2, DCO15)	
820 30(i) Changes	Yes (Doc. & Change Control)	Yes (DC02, DC013)	
820 10(i) DHF	Yes (Doc. & Change Control)	Yes (DCO2)	
820 40 Document Controls	Yes	Yes (P&PCO2L, SPCO2L)	
820, 40/a) Approval and Distrib	Yes	Yes (P&PCO2L, SPCO2L)	
820.40(a) 7.ppioral and 820.40(b) Changes	Yes	Yes (P&PCO2L, SPCO2L)	(V) G (1) (V)
920 (O Direbasing Controls	Yes	Yes (DCO5L, P&PCO2, SPCO2)	Add 820.50 cite to P&PC and SPC FC Box (2)
820.30 Luising Commers	Yes	Yes (DCO5L, P&PCO2, SPCO2)	Covered by comment to 820.50 above
820 SO(h) Purchasing data	Yes	Yes (DCOSL, P&PCO2, SPCO2)	Covered by comment to 820.50 above
820.30(0) 1 distribution	Yes	No	Add as linkage to P&PCO2 & SPCO2
820 65 Traceability	Yes	No (indirectly through review of DHR)	Add as linkage to P&PCO2 & SPCO2
820.70 P&PC	Section Title	Section Title	
820.70(a) General	Ycs	Yes (P&PCO2, SPCO2)	13) See 170 See 18 See 18
820 70(b) Changes	Yes (Doc. & Change Control)	Yes (DCO13)	Add 820.70(8) cite to UC FC Box (13)
820 70(c) Envir Control	Yes (Fac. & Equip.)	Yes (P&PCO2, SPCO2)	Add 820.7 U(c) offer to fractional action to Box (2)
020 70(d) Personnel	Yes	Yes (P&PCO6, SPCO5)	Add 820.25 and 870.70(d) cites to Port of the Dox (g) and 310.10 Dox (g)
020.70(a) reisolillei	Yes (Fac. & Equip.)	Yes (P&PCO2, SPCO2)	Add 820.70(e) cite to P&PC and SPC FC Box (2)
820.70(e) Containmation		No	Add new para, to pp. 85 & 98, just prior to "Verity that the control para.
520.70(1) Dunaings			To state: "Verify that the building is of suitable design and contains sufficient space to perform necessary operations." Add 820.70(f) cite to
		VEC ON GOOD ST	PORTUGATOR SPUT FULDOX (2)
820 70(s) Equipment	Yes	Yes (P&PCO2, SPCO2)	Add 620.70(g) cite to 1 ct 1 c 200 (z)
820 70(h) Manufact. Mat'l	Yes	Yes (P&PCO2, SPCO2)	Aud 620.70(11) VIC 10 1010 and 51010 500 (1)
920,70(i) Automated processes	Yes	Yes (P&PCOS, SPCO4)	
SZU, /UL) Automated processes			

SIT Validation Item G4; Provide broad and adequate coverage of the Quality system Regulation when conducting a comprehensive Quality system inspection. y: MC = Management Controls DC = Design Controls CAPA = Corrective and Preventive Actions P&PC = Production and Process Controls SPC = Sterilization Process Controls O2... = Objective 1, Objective 2, etc. L = Linkage FC = Flow Chart Examples: 820.20(a) Quality Policy is covered by QSIT "MCO1" and "MCO2" = Management Control objectives 1 and 2; If the requirement is covered by QSIT "P&PCO2L", it is covered by a "Linkage" from P&PC Objective 2. G4 Activity 1 Attach. 1 3 pp.

Quality System Regulation	CSO Nelson's Alignment	QSIT Coverage	Comments
820.75 Process validation	Section Title	Section Title	
820.75(a) validation procedures	Yes	Yes (P&PCO4)	Add 820.75(a) cite to P&PC FC Box (4) and SPC FC Box (1) add statement re: procedures to SPCO1 Narrative p. 93 para. 1 "Validation studies (according to established procedures) are required", and para. 3, sentence 2, "must include a review of the established validation procedures and verification"
820.75(b) monitoring and control	Yes	Yes (P&PCO2, P&PCO3, P&PCO6, SPCO2, SPCO2, SPCO3, SPCO3, SPCO3)	
820.75(c) changes, deviations	Yes	Yes (DCO13, P&PCO2, SPCO2)	Add 820.75(c) cite to P&PC FC Box (4) and SPC FC Box (1)
820.80 Acceptance Activities	Section Title	Section Title	
820.80(a) General	Yes	Yes (P&PCO2, SPCO2)	Add 820.80 cite to P&PC and SPC FC Box (2)
820.80(b) Receiving	Yes (Mat'l Control)	Yes (P&PCO2, SPCO2)	Covered by comment to 820.80(a) above
820.80(c) In-process	Yes	Yes (P&PCO2, SPCO2)	Covered by comment to 820.80(a) above
820.80(d) Final	Yes	Yes (P&PCO2, SPCO2)	Covered by comment to 820.80(a) above
820.80(e) Acc. Records	Yes	Yes (P&PCO2, SPCO2)	Covered by comment to 820.80(a) above
820.86 Acc. Status	Yes	No	Add linkage to P&PCO2 and SPCO2
820,90 Nonconforming product	Section Title	Section Title	
820,90(a) Control	Yes	Yes (P&PCO3, SPCO3)	
820.90(b) Review and Disposit.	Yes	Yes (P&PCO3, SPCO3)	
820.100 CAPA	Section Title	Section Title	
820.100(a) CAPA Procedures	Yes	Yes (DCOSL, CAPAOI – CAPAO10)	
820.100(b) CAPA documentation	Yes	Yes (CAPAO9)	
820.120 Device Labeling	Yes	Yes (DCO5L)	p. 83 "NOTE", make the existing note "1." Add a note to state: "2. If Device Labeling is the process chosen, include in your inspection coverage
			of the requirements of "820.120 Device Labeling".
820.120(a) Label integrity	Yes	oV.	Covered by comment to 820.120 above
820.120(b) Labeling inspection	Yes	ν.	Covered by comment to 820.120 above
820.120(c) Labeling storage	Yes	No	Covered by comment to 820.120 above
820.120(d) Labeling operations	Yes	No	Covered by comment to 820.120 above
820.120(e) Control number	Yes	No	Covered by comment to 820.120 above
820.130 Device packaging	Yes	Yes (DC01 – DC015)	Add linkage to P&PCO2, SPCO2
820.140 Handling	Yes	No	Add linkage to P&PCO2, SPCO2
820.150 Storage	Section Title	Section Title	
820.150(a) Proc. control	Yes	No	Add 820.150 linkage to P&PCO2, SPCO2
820.150(b) Proc. Rec. & dispatch	Yes	No	Covered by comment to 820.150(a) above
820.160 Distribution	Section Title	Section Title	
820,160(a) Procedures	Yes	No	Add 820.160 linkage to P&PCO2. SPCO2
820.160(b) Records	Yes	No	Covered by comment to 820.160(a) above
820.170 Installation	Section Title	Section Title	777701010
820.170(a) instruct.s & proc.s	Yes	°Z	Add as "linkages" following narrative of CAPAO4" important linkages for this activity include 820.80 Acceptance Activities, 820.90 Nonconforming Product, 820.170 Installation, 820.198 Complaint Files and 820.200
			Servicing."
820,170(b) install. & records	Yes	No	Covered by comment to 820.170(a) above
820 180 Records	Yes	No	Add 820.180 linkage to P&PCO2, SPCO2
820 180(a) Confidentiality	Yes	No	Covered by comment to 820.180 above
820 180(h) Retention	Yes	No	Covered by comment to 820.180 above
820 180(c) Excentions	Yes	Yes (MCOS, CAPAO2)	
820.180(C) EXCEPTIONS	Yes	Yes (DCO15, P&PCO2, SPCO2)	
ZIAIT X	?		

SIT Validation Item G4: Provide broad and adequate coverage of the Quality system Regulation when conducting a comprehensive Quality system inspection.

(ey: MC = Management Controls DC = Design Controls CAPA = Corrective and Preventive Actions P&PC = Production and Process Controls SPC = Sterilization Process Controls

(1, 02... = Objective 1, Objective 2, etc. L = Linkage FC = Flow Chart Examples: 820.20(a) Quality Policy is covered by QSIT "MCO!" and "MCO2" = Management Control

(b) bjectives 1 and 2; If the requirement is covered by QSIT "P&PCO2L", it is covered by a "Linkage" from P&PC Objective 2. G4 Activity 1 Attach. 1 3 pp.

4	CCO Maleon's Alignment	OSIT Coverage	Comments
Quality System Regulation	COO MEISON & DUBHINGING	Vi- (DOOIS DEBOO)	
820 181(c) OA procedures	Yes	res (DCO13, rarcoz, arcoz)	
820 181(d) nkg & laheling spec.s	Yes	Yes (DCO15, P&PCO2, SPCO2)	
820 181(a) Install Maint Serv	Yes	Yes (DCO15, P&PCO2L, SPCO2L)	
270 184 DHR	Yes	Yes (P&PCO2, SPCO2)	
820 184(a) dates of manuf	Yes	Yes (P&PCO2L, SPCO2L)	
820.184(h) quantity manuf	Yes	Yes (P&PCO2L, SPCO2L)	
820 184(c) quantity released dist.	Yes	Yes (P&PCO2L, SPCO2L)	
820 184(d) accentance records	Yes	Yes (P&PCO2, SPCO2)	
820 184(e) prim. ID label(ing)	Yes	Yes (P&PCO2L, SPCO2L)	
820 184(A ID Control Num.	Yes	Yes (P&PCO2L, SPCO2L)	
820 186 OSB	Yes	Yes (P&PCO2, P&PCO6, SPCO2, SPCO5)	
820 198 Complaint Files	Section Title	Section Title	
820 198(a) Compl. Procedures	Yes	Yes (CAPAO1)	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
020 100(L) Comm! Day, 8, Eval	Vec	Yes (CAPAOI)	Covered by comment to 820.1 / U(a) above
820 108(c) Compl. Invest	Yes	Yes (CAPAO1)	Covered by comment to 820.170(a) above
920.108(4) 803 804 Comple	Yes	Yes (CAPAO1)	Covered by comment to 820.170(a) above
620.196(d) 603, 604 Compliance	Ves	Yes (CAPAOI)	Covered by comment to \$20.170(a) above
820.198(e) Invest. Necord	**** Ver	Yes (CAPAOI)	Covered by comment to 820.170(a) above
820.198(t) rec. reas. access.	Vac	Yes (CAPAOI)	Covered by comment to 820.170(a) above
820.198(g) rec. access. m US	LV3	Section Title	
820.200 Servicing	Section this	Vec (CAPAOI)	Covered by comment to 820.170(a) above
820.200(a) instruct.s and proc.s	res	(CABAO1)	Covered by comment to 820.170(a) above
820.200(b) Ser. Rpt. Analysis	Yes	163 (CAFACI)	Covered by comment to 820.170(a) above
820 20070 803 804 Ser. Ruts.	Yes	Yes (CAFAUI)	0.000
820.200(d) Ser Rot Document.	Yes	Yes (CAPAOI)	Covered by comment to \$20.170(a) above
SOUD TAO Chatierical Techniques	Yes	Yes (CAPAO2, CAPAO3, CAPAO5, CAPAO6,	
00000000000000000000000000000000000000		P&PCO2, SPCO2)	
820.250(a) Proc.s to ID techn.s	Yes	Yes (CAPAO2, CAPAO3, CAPAO5, CAPAO6, P&PCO2)	
	1/	Yes (P&PCO2, SPCO2)	
820.250(b) Proc.s for sampling	res		

# **QSIT VALIDATION WORKSHEET**

Item #	Goal/Outcome	
G4	Quality System Regulation	Coverage
Term <sup>1</sup>	Type of activity (test or analysis)	Parameter(s) to be measured
Short Term	Analysis	Evaluate whether the instructions in the QSIT Handbook adequately address the requirements of the quality system regulation (QSR), and whether the inspection strategy assesses the quality system.
Scope and nature of the process to be followed.2	executives will compare the qual will determine if the QSIT Hand document their findings in a writ Hewlett-Packard; Rich Farb, Bat Kopesky, Medtronic, Inc.; David Corporation; Nancy Singer, HIM Wurzel, Becton Dickinson and C	ves, regulatory consultants, and trade association lity system regulation with the QSIT Handbook. They book covers the key elements of the QSR. They will tten report. The industry group consists of Don Barth, exter Healthcare; Ron Johnson, Quintiles BRI; Ken I Link, Expertech; Susan Moritz, Boston Scientific IA; Robert Turocy, Picker International; and Bob Company. Attachment I contains biographical expresentatives. This activity is to be completed by
Acceptance criteria (if known)	Consensus among the group members.	
Extent to which the activity measures/confirms		Subjective measurements by qualified experts and
how well the goal/outcome has been met. <sup>3</sup> (strengths and weaknesses of this validation activity)		professionals.
best approac	y the activity represents one of the hes to measuring the ent of the goal/outcome.	Two expert parties (an industry group and an FDA group) will perform this analysis independently. If the two analyses are reasonably congruent, that should provide a high degree of confidence in the findings.

<sup>&</sup>lt;sup>1</sup> Short term = pre-deployment event, long-term = post-deployment event
<sup>2</sup> Describe who, what, where, when, and how. Include an identification of baseline data that may be useful for comparing QSIT performance to the existing approach.
<sup>3</sup> Include a discussion of any limitations in the ability of the activity to objectively measure the goal/outcome.

### **BIOGRAPHICAL SKETCHES**

Donald J. Barth is the regulatory staff manager for the Medical Products Group (MPG) of Hewlett Packard (HP). He is responsible as a senior representative and negotiator for all of HP's Washington-based medical device regulatory initiatives. He helps to influence the programs and policies that support compliance with medical device laws in all of the countries in which MPG conducts business, as well as the group-wide implementation of ISO 9000 compliance programs. Mr. Barth began his career as a design engineer specializing in electronic hardware and firmware for airborne computer systems. He joined Hewlett Packard in 1973 as a marketing support engineer. Subsequently, he held several positions in manufacturing related to systems integration and testing. He then joined the R&D group as systems integration manager of several different computer-based products, with a particular focus on tools and methodologies to ensure high quality products. He earned a master's in electrical engineering at Columbia University, and a bachelor's in electrical engineering at New York University.

Richard Farb is corporate director of regulatory compliance for Baxter International. Mr. Farb started his career with Baxter in 1965 in biomedical engineering research and development. He has experience in various positions and divisions of Baxter and has been vice president of regulatory affairs and quality assurance for two divisions. His current responsibilities include monitoring new regulatory requirements and worldwide harmonization efforts for regulatory requirements. He is the convener of ISO TC210 WG3, which has ISO jurisdiction for medical device nomenclature and symbols for use in labeling for medical devices. Mr. Farb has a bachelor's degree with concentrations in physiology and chemistry from Southern Illinois University and a master's degree from the University of Chicago.

Ronald M. Johnson is vice president for Quintiles Consulting global operations, responsible for management of the division's West Coast operations. Mr. Johnson directs and overseas the planning, development, and implementation of the Quality System Regulation including design control provisions, adverse event reporting requirements, drug and biologics GMPs, GCPs, and ISO 9000. He was with the FDA for thirty years, serving a wide array of positions in both headquarters and the field organization. During his last twelve years, he served as District Director and Regional Director in FDA's field force and as Director, Office of Compliance, Center for Devices and Radiological Health. In these positions Mr. Johnson was directly responsible for many of the agency's contemporary enforcement and compliance initiatives, particularly in the medical device area. As Director of FDA's Pacific Region, he initiated an industry outreach program to facilitate interaction and collaboration between FDA and the regulated industry.

**Ken Kopesky** is the director of corporate compliance and audit for Medtronic, Inc. His responsibilities are managing the overall compliance of Medtronic businesses regarding quality, regulatory, and clinical activities. He has been with Medtronic for 27 years and has held management positions in quality assurance, return product analysis, service, operations, and manufacturing development. He also is a member of GHTF Study Group 2 and serves on a number of association committees.

**David M. Link** has more than 35 years of experience in the medical device industry. While at Hewlett Packard Company, he served in research and development, manufacturing, and marketing functions. From 1970 to 1980, he managed the medical device program at FDA. As

the first director of the Bureau from 1974 to 1980, he was instrumental in establishing the regulatory philosophy, which permitted growth and encouraged innovation in the U.S. medical device industry. Mr. Link received his B.S. in physics from the Massachusetts Institute of Technology, his M.S. in nuclear physics from the University of Illinois, and his M.B.A. from the Harvard Graduate School of Business Administration.

Susan Moritz is the manager of corporate compliance for Boston Scientific Corporation, a multinational manufacturer and distributor of medical devices. Ms. Moritz has world-wide responsibility for the assessments of the quality systems utilized by Boston Scientific and its various divisions. Her group develops and conducts audit programs that assess the degree and extent of compliance to applicable regulations and/or practices such as the Quality System Regulation, ISO 9001, ISO 13485 and the Medical Device Directives. In this role, Ms. Moritz coordinated and conducted training for BSC personnel world wide on the design control requirements of the Quality System Regulation. Ms. Moritz has been working in the quality arena for the past 11 years and holds a bachelor's degree in biology and a master's degree in business administration.

Nancy Singer is special counsel at HIMA. In this capacity she serves as counsel for FDA enforcement matters. Previously, she was executive director of the Food and Drug Law Institute. Her food and drug career began as an attorney at the United States Department of Justice where she did litigation for the Food and Drug Administration. Subsequently she was a partner at the law firm of Kleinfeld, Kaplan and Becker. Ms. Singer received her B.S. from Cornell University, and her J.D. and LL.M. degrees from New York University Law School.

Robert L. Turocy is the corporate regulatory affairs & compliance manager for Picker International, Inc. and has more than 28 years of experience in the medical device imaging industry. During the first ten years at Picker, Mr. Turocy worked in the engineering department as a mechanical designer and a product safety specialist. The last eighteen years, he has an extensive background and experience in the regulatory requirements for medical imaging devices. Mr. Turocy is a Picker representative to NEMA Committees (Legislative & Regulatory, GMP, International, and a Chairman of the X-Ray Technical & Government Relations). He has served as a member of the FDA Technical Electronic Product Radiation Safety Standards Advisory Committee. He is a member of RAPS, AAMI, and ASQ wherein he is a Certified Quality Auditor. He is a member of IEC Working Group 15 and an alternate to other IEC Working Groups.

Robert D. Wurzel is vice president, regulatory and quality affairs at Becton Dickinson and Company in Franklin Lakes, New Jersey. Mr. Wurzel joined Becton Dickinson in 1989 and was elected a Corporate Officer in October 1994. Since 1970, Mr. Wurzel has held senior quality and regulatory affairs management positions in several international healthcare companies. Prior to his industry experience, Mr. Wurzel spent 18 years in public health and clinical laboratories. Mr. Wurzel presently is the U.S. industry representative on Working Group 4 of the Medical Device Global Harmonization Task Force. This Working Group is pursuing the harmonization of regulatory auditing worldwide. He is a member of the ANSI and AAMI Boards of Directors and was a 1997 Malcolm Baldrige National Quality Award Examiner. Mr. Wurzel holds an M.B.A. from Pepperdine University and has an undergraduate degree from Bowling Green State University (Ohio).

# QSIT VALIDATION ACTIVITY REPORT

Item #	Goal/Outcome	
G4	Quality System Regulation	Coverage
Activity #	Type of activity (test or analysis)	Parameter(s) to be measured
2	Analysis	Evaluate whether the instructions in the QSIT Handbook adequately address the requirements of the quality system regulation (QSR) and whether the inspection strategy adequately assesses the quality system
Acceptance	There was consensus among the	group members:
Criteria	Ken Kopesky, Medtronic, Inc.;	ch Farb, Baxter Healthcare; Ron Johnson, Quintiles BRI; David Link, Expertech; Susan Moritz, Boston Scientific MA; Robert Turocy, Picker International; and Bob Wurzel,
Summary of Results	The instructions in the QSIT Handbook expressly cover the four major subsystems of the QSR and can be linked to the remaining provisions in the QSR as indicated in the attached chart. Each firm's method of applying the various provisions of the QSR will depend on its products and operations. Ultimately, the depth (sampling tables) and breadth (linkages) of the inspection will depend on the risk of the device, and the firm's compliance with the requirements.	
Conclusion	The findings do [X] do not [] meet the acceptance criteria for this activity.	
Additional Comments	;	
Activity Cham	mpion(s) Nancy Singer, Special Counsel, HIMA Ken Kopesky, Director of Corporate Compliance and Audit, Medtronic, Inc.	

Rev. 2/12/99

### Chart Indicating Linkages Between QSIT and the Quality System Regulation

The left column is a breakdown of the QSIT coverage in outline form. The right column is a listing of the sections of 21CFR 820. The right column also identifies the link(s) to the QSIT Outline.

### QSIT Outline1

### A Management Controls:

- 1. Quality policy
- 2. Management review
- 3. Quality audit
- 4. Quality plan
- 5. Quality system procedures
- 6. Organizational structure, responsibility, authority and necessary resources
- 7. Management representative
- 8. Suitability and effectiveness of the quality system is reviewed

### B Design Controls:

- 1. Design control procedures
- 2. Design plan assigned responsibilities, interfaces and risk analysis
- 3. Design inputs
- 4. Design outputs essential for proper functioning
- 5. Acceptance criteria
- 6. Design verification
- 7. Design validation user needs and intended uses
- 8. Design validation no unresolved discrepancies
- 9. Software validation
- 10. Performance of risk analysis
- 11. Validation with production samples
- 12. Design change control
- 13. Design reviews
- 14. Design Transfer

### C Corrective and Preventive Action

- 1. Identify appropriate sources of information
- 2. Information is analyzed
- 3. Information is complete, accurate and timely
- 4. Statistical methods and completeness
- 5. Failure analysis commensurate with the risks
- 6. Root cause analysis
- 7. Appropriate actions taken and documented
- 8. Information disseminated management review

### D Production and Process Controls

- 1. Product and Process Control Procedures
- 2. Controls and monitors
- 3. Device History Records
- 4. Nonconformity actions
- 5. Equipment adjustment, calibration and maintenance
- 6. Validation study
- 7. Software validation
- 8. Personnel qualifications

# 21 CFR Section 820 Plus Linkages to the QSIT Outline on the Left

- 820.1 Scope none
- 820.3 Definitions none
- 820.5 Quality system A1-A8
- 820.20 Management responsibility A1-A8
- 820.22 Quality audit A3
- 820.25 Personnel A6, D8
- 820.30 Design controls B1-B14
- 820.40 Document controls A5, A8, B1, B2, B12, B13, B14, C3, C7, C8, D1, D3, D6-D8
- 820.50 Purchasing controls B5, B6, B12, C6, C7, D2
- 820.60 Identification A5, B14, D1, D2
- 820.65 Traceability A5, B14, D1, D2
- 820.70 Production and process controls A4, A5, C2 C7, D1 D8
- 820.72 Inspection, measuring, and test equipment A5, C2 C7, D1 D8
- 820.75 Process validation B6 B8, D5 D7
- 820.80 Receiving, in-process, and finished device acceptance A4, A5, C1 C8, D1 D5
- 820.86 Acceptance status A4, D1, D2
- 820.90 Nonconforming product A2, A4, A5, C1 C8
- 820.100 Corrective and preventive action C1 C8
- 820.120 Device labeling A5, B3, B7, D1, D2
- 820.130 Device packaging B3, B7, D1, D2
- 820.140 Handling A5, D1, D2
- 820.150 Storage A5, D1, D2
- 820.160 Distribution A5, D1, D2
- 820.170 Installation A5, B3, B4, B7, D1, D2
- 820.180 Records, General requirements A4, A5, B2
- 820.181 Device master record A4, A5, B4, B5, B14, D1, D2
- 820.184 Device history record A4, A5, D3
- 820.186 Quality system record A4, A5, B12, B14, D1 D8
- 820.198 Complaint files A5, C1 C8, D4
- 820.200 Servicing A4, A5, B7, D1, D2
- 820.250 Statistical techniques A4, A5, B2, B5, B6, B7, B10, B11, C4, D6

<sup>&</sup>lt;sup>1</sup> The QSIT Outline numbering does not relate to the numbering in the QSIT Handbook.